<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539902</url>
  </required_header>
  <id_info>
    <org_study_id>CT 11-03</org_study_id>
    <nct_id>NCT01539902</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis</brief_title>
  <acronym>hUC-MSC-SLE</acronym>
  <official_title>A Randomized, Double Blind, Parallel Group, Placebo Controlled Research of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoMed &amp; Beike</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoMed &amp; Beike</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy measure of hUC-MSC in the treatment of proliferative lupus nephritis on
      remission of lupus nephritis (combined partial and complete remission) in terms of
      stabilization and improvement in renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:

        1. Male or non-pregnant females age 16 to 65 years inclusive.

        2. Written informed consent obtained from patient or parents/guardian.

        3. Patients with SLE fulfilling American Rheumatism Association criteria and SLEDAI score&gt;8
           or BILAG score A/B.

        4. Patients with newly diagnosed World Health Organization (WHO) Class III or IV Lupus
           Nephritis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and Safety</measure>
    <time_frame>6 months</time_frame>
    <description>The efficacy measure is remission of nephritis (combined partial and complete remission) at 6 months defined as
Stabilization or improvement in renal function and
Urinary RBC of less than 10 per HPF and
Reduction of proteinuria to less than 3 g/day if baseline proteinuria was more than 3 g/day and at least a 50% reduction in proteinuria, or to less than 1 g/day if the baseline proteinuria was in the subnephrotic range.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Human Umbilical Cord derived MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Umbilical Cord derived MSCs</intervention_name>
    <description>Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion</description>
    <arm_group_label>Human Umbilical Cord derived MSCs</arm_group_label>
    <other_name>Allogeneic stem cells derived from umbilical cord</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <other_name>Immunosupressive agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant females age 16 to 65 years inclusive.

          2. Written informed consent obtained from patient or parents/guardian.

          3. Patients with SLE fulfilling American Rheumatism Association criteria and SLEDAI
             score&gt;8 or BILAG score A/B.

          4. Patients with newly diagnosed World Health Organization (WHO) Class III or IV Lupus
             Nephritis

        Exclusion Criteria:

        Patients with any of the following are not eligible for enrollment into the study:

          1. Pregnant or nursing woman or women of childbearing potential except if
             post-menopausal, surgically sterile or using accepted method(s) of birth control or
             having negative pregnancy test.

          2. Participation in any research in which the patient received an investigational product
             within 30 days preceding the screening phase of this study.

          3. Those persons directly involved in the conduct of the study.

          4. Serum creatinine more than 250 Âµmol/L.

          5. White blood cell (WBC) count of less than 3.5 X 109/L.

          6. Active peptic ulcer disease.

          7. Active systemic infection.

          8. History of alcohol or substance abuse.

          9. History of malignancy within previous 5 years.

         10. Any serious medical conditions or disability, which in the opinion of the
             investigator, would interfere with treatment or assessment or preclude completion of
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Second Affiliated Hospital &amp; SLE Research Centre, Kunming Medical University, Kunming China</name>
      <address>
        <city>Kunming</city>
        <state>Yunan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PeiLian Zhang, Dr</last_name>
      <email>mzczpl1968@163.com</email>
    </contact>
    <investigator>
      <last_name>DanQi Deng, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PeiLian Zhang, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSC for the treatment of Lupus Nephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

